Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 10/20 cls
Acorda (ACOR) Banc of America Securities David Witzke Price target Buy 1% $17.03
Lazard Joel Sendek Price target Buy
Witzke raised his target to $24 from $12 based on increased penetration assumptions for ACOR's Fampridine-SR in multiple sclerosis (MS) patients with walking disability. The sustained-release formulation of 4-aminopyridine (4-AP) met all three endpoints in a recent Phase III trial (see BioCentury, Oct. 2).
Sendek raised his target to $22 from $14, forecasting rapid approval and uptake of Fampridine-SR. He expects FDA approval in early 2009.
Aeterna Zentaris (TSX:AEZ; AEZS) Dundee David Martin Price target Market outperform 6% $5.36
Martin lowered his target to $9 from $10 after the company sold 24% of its holdings in Atrium

Read the full 1331 word article

How to gain access

Continue reading with a
two-week free trial.